Molecular Characterization of Mammalian bHLH-PAS Transcription Factors
哺乳动物 bHLH-PAS 转录因子的分子表征
基本信息
- 批准号:9324331
- 负责人:
- 金额:$ 38.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-01 至 2020-05-31
- 项目状态:已结题
- 来源:
- 关键词:ARNT geneAgonistArchitectureAryl Hydrocarbon ReceptorBindingBiochemicalBiological AssayBiologyBiopsyCell physiologyCellsChemicalsComplementComplexCrystallizationDNADNA BindingDNA Binding DomainDimensionsDimerizationDiseaseDrug Metabolic DetoxicationFamilyFamily memberGene ExpressionGenesGeneticGenetic TranscriptionGoalsHelix-Turn-Helix MotifsHeterodimerizationHumanHypoxia Inducible FactorImmunityInvestigationKnowledgeLigand BindingLigandsLinkLocationMalignant NeoplasmsMammalsMapsMediatingMetabolicMolecularMutationNeoplasm MetastasisNeuronsPathway interactionsPhysiologicalPositioning AttributePropertyProteinsReportingResponse ElementsSchizophreniaSeriesSignal TransductionStructureStructure-Activity RelationshipSubgroupTissuesTranscriptional RegulationX-Ray CrystallographyXenobioticsaryl hydrocarbon receptor ligandautism spectrum disorderbHLH-PAS factor HLFbasedimerhigh throughput screeninghuman tissuehypoxia inducible factor 1neuropsychiatric disorderprogramsprotein functionpublic health relevanceresponsesensorsmall moleculetooltranscription factortumor initiation
项目摘要
DESCRIPTION (provided by applicant): The basic Helix-Loop-Helix-Per/Arnt/Sim (bHLH-PAS) family is a major group of transcription factors in mammals. Functional heterodimers in this family form via a tissue-restricted subunit, such as the hypoxia- inducible factors (HIFs), neuronal PAS (NPAS) proteins, or aryl hydrocarbon receptor (AHR), and a common dimerization subunit, such as aryl hydrocarbon receptor nuclear translocator (ARNT). Family members contain tandem PAS domains and a DNA-binding domain. PAS domains have the potential to act as molecular sensors and transmit signals to regulate the activities of these transcription factors. The HIF subgroup within the family regulates genetic programs critical in human tumor initiation, progression, invasion and metastasis. Several NPAS proteins have been genetically linked to human neuropsychiatric disorders. AHR recognizes and responds to a spectrum of xenobiotic molecules and drives gene programs necessary for detoxification. Our current knowledge about the architectures of these heterodimers, their ligand-binding pockets, and ligand- responsive activities is limited. Therefore, we have begun to conduct detailed structural investigations into several bHLH-PAS heterodimers in complexes that include bound DNA and small-molecule ligands. Our proposed structural characterizations will be complemented with chemical biology and cell-based studies to deepen our understanding of structure-function relationships in this family. The overall goals of this proposal include characterizing distinct bHLH-PAS heterodimers by X-ray crystallography, interrogating the location and composition of their ligand-binding pockets, identifying new tool compounds, and examining how ligands and disease-linked mutations manifest their actions through protein architectures.
描述(由申请人提供):基本螺旋-环-螺旋-Per/Arnt/Sim(bHLH-PAS)家族是哺乳动物中的一组主要转录因子。该家族中的功能性异二聚体通过组织限制性亚基(例如缺氧诱导因子(HIF)、神经元PAS(NPAS)蛋白或芳烃受体(AHR))和常见的二聚化亚基(例如芳烃受体核转运子(ARNT))形成。家族成员包含串联PAS结构域和DNA结合结构域。PAS结构域具有作为分子传感器和传递信号以调节这些转录因子的活性的潜力。该家族中的HIF亚组调节在人类肿瘤发生、进展、侵袭和转移中至关重要的遗传程序。几种NPAS蛋白质与人类神经精神疾病有遗传联系。AHR识别并响应一系列异生物质分子,并驱动解毒所需的基因程序。我们目前对这些异二聚体的结构、它们的配体结合口袋和配体响应活性的了解是有限的。因此,我们已经开始进行详细的结构调查几个bHLH-PAS异二聚体的复合物,包括结合的DNA和小分子配体。我们提出的结构表征将与化学生物学和基于细胞的研究相结合,以加深我们对该家族结构-功能关系的理解。该提案的总体目标包括通过X射线晶体学表征不同的bHLH-PAS异源二聚体,询问其配体结合口袋的位置和组成,鉴定新的工具化合物,并研究配体和疾病相关突变如何通过蛋白质结构表现出它们的作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
FRAYDOON RASTINEJAD其他文献
FRAYDOON RASTINEJAD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('FRAYDOON RASTINEJAD', 18)}}的其他基金
Identification of Hypoxia-Inducible Factor-2alpha Activators for Chronic Kidney Disease Anemia
慢性肾病贫血缺氧诱导因子 2α 激活剂的鉴定
- 批准号:
9906953 - 财政年份:2018
- 资助金额:
$ 38.51万 - 项目类别:
Identification of Hypoxia-Inducible Factor-2alpha Activators for Chronic Kidney Disease Anemia
慢性肾病贫血缺氧诱导因子 2α 激活剂的鉴定
- 批准号:
9577222 - 财政年份:2018
- 资助金额:
$ 38.51万 - 项目类别:
Structural Biology of Multi-Domain Nuclear Receptor Complexes
多域核受体复合物的结构生物学
- 批准号:
9159659 - 财政年份:2017
- 资助金额:
$ 38.51万 - 项目类别:
Molecular Characterization of Mammalian bHLH-PAS Transcription Factors
哺乳动物 bHLH-PAS 转录因子的分子表征
- 批准号:
9113818 - 财政年份:2016
- 资助金额:
$ 38.51万 - 项目类别:
Identification of Rev-Erb alpha/beta nuclear receptor modulators
Rev-Erb α/β 核受体调节剂的鉴定
- 批准号:
8671893 - 财政年份:2014
- 资助金额:
$ 38.51万 - 项目类别:
Identification of Allsoteric Ligands for Hepatic Nuclear Factor 4-alpha
肝核因子 4-α 变构配体的鉴定
- 批准号:
8421932 - 财政年份:2012
- 资助金额:
$ 38.51万 - 项目类别:
Identification of Allsoteric Ligands for Hepatic Nuclear Factor 4-alpha
肝核因子 4-α 变构配体的鉴定
- 批准号:
8775220 - 财政年份:2012
- 资助金额:
$ 38.51万 - 项目类别:
Structural Characterization of Metabolic Gene Regulators
代谢基因调控因子的结构表征
- 批准号:
8728842 - 财政年份:2011
- 资助金额:
$ 38.51万 - 项目类别:
Structural Characterization of Metabolic Gene Regulators
代谢基因调控因子的结构表征
- 批准号:
8538964 - 财政年份:2011
- 资助金额:
$ 38.51万 - 项目类别:
Structural Characterization of Metabolic Gene Regulators
代谢基因调控因子的结构表征
- 批准号:
8339923 - 财政年份:2011
- 资助金额:
$ 38.51万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 38.51万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 38.51万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 38.51万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 38.51万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 38.51万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 38.51万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 38.51万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 38.51万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 38.51万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 38.51万 - 项目类别: